Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mesa LaboratoriesMLAB -0.36%76 EV-to-EBIT is 28.63 as of Jul. 14, 2026, which is 71% below its 10-year median of 99.27. GuruFocus rates MLAB with a GF Score™ of 76/100 and a GF Value™ of $116.28 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,773 Hardware companies, Mesa Laboratories ranks worse than 58.77% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Mesa Laboratories's Enterprise Value for the quarter that ended in Mar. 2026 was $616.8 Mil.
Mesa Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $22.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mesa Laboratories EV-to-EBIT Related Terms
Mesa Laboratories EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Mesa Laboratories's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Scientific & Technical Instruments subindustry, Mesa Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mesa Laboratories EV-to-EBIT vs Hardware Industry
For the Hardware industry and Technology sector, Mesa Laboratories's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Mesa Laboratories's EV-to-EBIT falls into.
Mesa Laboratories's current Enterprise Value is $650.0 Mil.
Mesa Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $22.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mesa Laboratories (MLAB) has a EV-to-EBIT of 28.63 as of Jul. 14, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Mesa Laboratories and its competitors. This is 71% below median its historical median of 99.27. According to the industry distribution chart, Mesa Laboratories ranks #1042 out of 1773 companies in the Hardware industry, placing it in the top 58.8%.
Is Mesa Laboratories' EV-to-EBIT too high?
Mesa Laboratories' current EV-to-EBIT of 28.63 is 71% below median its 10-year median of 99.27. The Hardware industry median EV-to-EBIT is 21.84. Mesa Laboratories' value of 28.63 is 31.1% above this industry median. Based on the distribution chart, Mesa Laboratories ranks #1042 out of 1773 companies in the Hardware industry, which is below the industry midpoint. Overall, Mesa Laboratories has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mesa Laboratories' EV-to-EBIT compare to AERG and USBC?
According to the Hardware industry distribution chart, Mesa Laboratories ranks #1042 out of 1773 companies for EV-to-EBIT. This places Mesa Laboratories in the lower half of its industry. The industry median EV-to-EBIT is 21.84. Mesa Laboratories' value of 28.63 is 31.1% above this benchmark. While the company's 10-year median is 99.27 vs. the industry median of 21.84, Mesa Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Hardware company?
The median EV-to-EBIT among Hardware companies is 21.84, based on 1,773 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mesa Laboratories's current EV-to-EBIT of 28.63 is 31.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Mesa Laboratories and its competitors. For the Hardware industry, the median EV-to-EBIT is 21.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mesa Laboratories's current EV-to-EBIT is 28.63, which is 71% below median its own 10-year median of 99.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mesa Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Mesa Laboratories (MLAB) is currently considered Modestly Undervalued. The stock's GF Value™ is $116.28, compared to a current price of $94.45 — trading 18.8% below its estimated fair value. The current EV-to-EBIT is 28.63, which is 71% below median its 10-year median of 99.27 and 31.1% above the Hardware industry median of 21.84. Mesa Laboratories' overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Mesa Laboratories (MLAB), the current EV-to-EBIT is 28.63 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mesa Laboratories (MLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Mesa Laboratories stock appears to be undervalued.
The current stock price of $94.45 is trading 18.8% below its estimated GF Value™ of $116.28.
GuruFocus considers Mesa Laboratories to be Modestly Undervalued.
Key valuation signals for MLAB:
EV-to-EBIT: 28.63 (71% below median its 10-year median of 99.27)
GF Value™: $116.28 vs. price of $94.45 (18.8% below fair value)
Industry Position: 31.1% above the Hardware median (#1042 of 1773)
No single metric tells the full story. See the MLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mesa Laboratories Inc manufactures life sciences tools and critical quality control solutions. It operates in four divisions: i) Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. ii) Clinical Genomics division develops, manufactures, and sells sensitive, low-cost, high-throughput genetic analysis tools and related consumables. iii) The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. iv) The Calibration Solutions division develops, manufactures, sells, and services quality control products.
76GF Score
Get the complete analysis for MLAB
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLAB has been successfully added to your 
